RudaCure, una empresa especializada en el desarrollo de tratamientos para trastornos sensoriales, anunció el 3rd that its tratamiento del dolor crónico (RCI002) ha sido seleccionada como a apoyoed proyecto by the Korea Drug Development Fund (KDDF), and that optimization investigación to derive a compuesto líder will now begin in earnest.
RudaCure's RCI002 is a compuesto that selectively inhibits the activity of TRPV1, a key target known for developing powerful analgésico no narcóticos. Según la empresa's preliminary investigación, the compuesto demostró TRPV1 inhibitory activity and reduced pain in dolor crónico animal models. Unlike existing TRPV1 antagonists, it does not cause abnormal fever, offering excellent eficacia analgésica with no significant efectos secundarios, giving it high potential for desarrollo as a safe tratamiento.
En particular, la empresa expects synergistic effects for the optimization investigación of RCI002 through joint execution of this apoyo proyecto with the team of Professor Park Cheol-gyu at Gachon University College of Medicine — a specialist in tratamiento del dolor desarrollo who is participating as the lead institution.
Source: BioTimes (http://www.biotimes.co.kr)